Marizyme Announces the Use of DuraGraft(R) as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf

DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Marizyme, Inc. (OTCQB: MRZM),... Devices, Cardiology Marizyme, DuraGraft, CABG
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news